543 related articles for article (PubMed ID: 31906999)
21. Risk factors of uncontrolled symptoms using the standard dose of second-generation H1 -antihistamines in chronic spontaneous urticaria children.
Koosakulchai V; Yuenyongviwat A; Sangsupawanich P
Asian Pac J Allergy Immunol; 2022 Jun; 40(2):121-125. PubMed ID: 32061244
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.
Saini SS; Bindslev-Jensen C; Maurer M; Grob JJ; Bülbül Baskan E; Bradley MS; Canvin J; Rahmaoui A; Georgiou P; Alpan O; Spector S; Rosén K
J Invest Dermatol; 2015 Jan; 135(1):67-75. PubMed ID: 25046337
[TBL] [Abstract][Full Text] [Related]
23. The Impact of Bilastine on Symptoms of Allergic Rhinitis and Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Abdelshafy AM; Abdallah SY; Hassan AF; Mohamed HA; Kamal NM; Ali ST; Abdelhaleem IA
Am J Rhinol Allergy; 2022 Sep; 36(5):684-694. PubMed ID: 35593100
[TBL] [Abstract][Full Text] [Related]
24. Bilastine in Refractory Chronic Spontaneous Urticaria: Disease Control and Cytokine Modulation in an Open-label Prospective Study.
De A; Singh S; Chakraborty D; Sarda A; Godse K
Indian J Dermatol; 2024; 69(2):132-136. PubMed ID: 38841225
[TBL] [Abstract][Full Text] [Related]
25. Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers.
Farré M; Pérez-Mañá C; Papaseit E; Menoyo E; Pérez M; Martin S; Bullich S; Rojas S; Herance JR; Trampal C; Labeaga L; Valiente R
Br J Clin Pharmacol; 2014 Nov; 78(5):970-80. PubMed ID: 24833043
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Up-dosing Antihistamines in Chronic Spontaneous Urticaria: A Systematic Review of the Literature.
Iriarte Sotés P; Armisén M; Usero-Bárcena T; Rodriguez Fernández A; Otero Rivas MM; Gonzalez MT; Meijide Calderón A; Veleiro B;
J Investig Allergol Clin Immunol; 2021 Jul; 31(4):282-291. PubMed ID: 33030434
[TBL] [Abstract][Full Text] [Related]
27. Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial.
Staevska M; Gugutkova M; Lazarova C; Kralimarkova T; Dimitrov V; Zuberbier T; Church MK; Popov TA
Br J Dermatol; 2014 Jul; 171(1):148-54. PubMed ID: 24472058
[TBL] [Abstract][Full Text] [Related]
28. An evaluation of remission rates with first and second line treatments and indicators of antihistamine refractoriness in chronic urticaria.
Ayse Ornek S; Orcen C; Church MK; Kocaturk E
Int Immunopharmacol; 2022 Nov; 112():109198. PubMed ID: 36115277
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis.
Nochaiwong S; Chuamanochan M; Ruengorn C; Awiphan R; Tovanabutra N; Chiewchanvit S
JAMA Dermatol; 2021 Nov; 157(11):1316-1327. PubMed ID: 34431983
[TBL] [Abstract][Full Text] [Related]
30. Comparing four immunosuppressive agents for chronic spontaneous urticaria-A network meta-analysis.
Bei W; Qian J; Zilu Q; Kai C; Ruili J; Feng H; Liuqing C
Int Immunopharmacol; 2023 Oct; 123():110577. PubMed ID: 37567010
[TBL] [Abstract][Full Text] [Related]
31. Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.
Martina E; Diotallevi F; Bianchelli T; Paolinelli M; Offidani A
Curr Pharm Biotechnol; 2021; 22(1):32-45. PubMed ID: 32603278
[TBL] [Abstract][Full Text] [Related]
32. Real-World Indian Experience of Switchover to Bilastine 40 mg/day in CSU Patient Refractory to Other Antihistamines at Double Dose.
De A; Shah B; Banodkar PD; Dhoot D; Chitnis K; Barkate H
Indian J Dermatol; 2023; 68(6):674-677. PubMed ID: 38371575
[TBL] [Abstract][Full Text] [Related]
33. Bilastine: a new nonsedating oral H1 antihistamine for treatment of allergic rhinoconjunctivitis and urticaria.
Wolthers OD
Biomed Res Int; 2013; 2013():626837. PubMed ID: 23956994
[TBL] [Abstract][Full Text] [Related]
34. Safety profile of bilastine: 2nd generation H1-antihistamines.
Scaglione F
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1999-2005. PubMed ID: 23242729
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study.
Okubo K; Gotoh M; Asako M; Nomura Y; Togawa M; Saito A; Honda T; Ohashi Y
Allergol Int; 2017 Jan; 66(1):97-105. PubMed ID: 27421817
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.
Yuan W; Hu S; Li M; Yang L; Liu L; Zheng M; Guo Z; Song Z; Zhang C; Diao Q; Xu J; Richard A; Patwardhan M; Lyu T; Uddin A; Fogel R; Ligueros-Saylan M; Zheng J
Dermatol Ther; 2022 Apr; 35(4):e15303. PubMed ID: 34984792
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria.
Rodríguez M; Vozmediano V; García-Bea A; Novák Z; Yáñez A; Campo C; Labeaga L
Eur J Pediatr; 2020 May; 179(5):801-805. PubMed ID: 31919579
[TBL] [Abstract][Full Text] [Related]
38. Fenebrutinib in H
Metz M; Sussman G; Gagnon R; Staubach P; Tanus T; Yang WH; Lim JJ; Clarke HJ; Galanter J; Chinn LW; Chu T; Teterina A; Burgess T; Haddon DJ; Lu TT; Maurer M
Nat Med; 2021 Nov; 27(11):1961-1969. PubMed ID: 34750553
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M; Ensina LF; Gimenez-Arnau AM; Sussman G; Hide M; Saini S; Grattan C; Fomina D; Rigopoulos D; Berard F; Canonica GW; Rockmann H; Irani C; Szepietowski JC; Leflein J; Bernstein JA; Peter JG; Kulthanan K; Godse K; Ardusso L; Ukhanova O; Staubach P; Sinclair R; Gogate S; Thomsen SF; Tanus T; Ye YM; Burciu A; Barve A; Modi D; Scosyrev E; Hua E; Letzelter K; Varanasi V; Patekar M; Severin T;
Lancet; 2024 Jan; 403(10422):147-159. PubMed ID: 38008109
[TBL] [Abstract][Full Text] [Related]
40. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
